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Background
The goal of this project is to develop T cells that
express chimeric antigen receptors (CARs) as an effec-
tive immunotherapy for glioblastoma (GBM), the most
aggressive, primary brain tumor in humans, which out-
come remains poor. IL13Ra2 is aberrantly expressed in
GBM and therefore it is a promising candidate for CAR
T cell immunotherapy. While other investigators have
generated IL13Ra2-targeted CARs using mutated forms
of IL13 as CAR binding domains, our studies indicate
that these CARs also recognize IL13Ra1, raising signifi-
cant toxicity concerns. To overcome this limitation we
have developed a high affinity IL13Ra2-specific scFv
(M47) that does not recognize IL13Ra1 and that was
used to generate scFv-based IL13Ra2-specific CAR
(M47-CAR T cells) and evaluate their function.
Methods
We constructed a panel of IL13Ra2-CARs containing
M47 as an ectodomain, a short spacer or long spacer
region (SSR, LSR), a CD28 transmembrane domain, and
endodomains that consist of signaling domains derived
from CD3ζ and co-stimulatory molecules (CD28.ζ,
CD28.OX40.ζ, CD28.ζ, CD28.41BB.ζ, 41BB.ζ) IL13Ra2-
CAR T cells were generated by retroviral transduction,
and their effector function was compared in vitro and in
a GBM xenograft model.
Results
While all CARs were expressed as judged by Western
blot analysis, CARs with a SSR and a CD28.41BB.ζ
endodomain were not expressed on the cell surface. In
cytotoxicity assays, IL13Ra2-CAR T cells only killed tar-
get cells that expressed IL13Ra2 and not IL13Ra1 con-
firming specificity. While all IL13Ra2-CAR T cells
secreted significant levels of IFNg in co-culture assays
with the IL13Ra2+ glioma cell line U373, only CAR
T cells with a short spacer region (SSR) secreted signifi-
cant amounts of IL2. In contrast, T cells expressing an
IL13Ra2-CAR with a deleted endodomain (M47-CAR.
D) did not recognize or kill any target cells. In vivo,
injection of IL13Ra2.SSR.CAR T cells with CD28.ζ,
CD28.OX40.ζ, or 41BB.ζ endodomains into U373 -bear-
ing mice resulted in regression of glioma xenografts and
a significant survival advantage with M47-CAR.SSR.
CD28.ζ T cell therapy providing the longest median over-
all survival (84 days vs 40 days for M47-CAR.SSR.D).
Conclusions
T cells redirected to IL13Ra2 with M47-CARs have
potent anti-tumor activity against glioma cells in vitro,
and induce the regression of established GBM xeno-
grafts. Our study adds to the growing literature that
there is an intricate interplay between scFVs, spacer
region, transmembrane domain and endodomain that
determine CAR function, and that there is no single
optimal configuration. M47-CARs may be of value in
the treatment of not only IL13Ra2-positive GBMs but
also other malignancies in which IL13Ra2 is expressed.
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